Lingyan Jiang

Statistics

Publications

Citations

343

H-Index

Active since

2024

Affiliations

Revolution Medicines (United States)(Current)

Dana-Farber Cancer Institute

Memorial Sloan Kettering Cancer Center

Broad Institute

Harvard University

Lingyan Jiang is an author at Revolution Medicines (United States) specializing in targeted cancer therapy, kras inhibitors, and ras family oncogenes.

ORCID

Publications per year

2024–2025

Publications

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato et al. · Cancer Discovery · 2024 · 281 citations · Full text

Medicine, Oncology, Pharmacology +17

A neomorphic protein interface catalyzes covalent inhibition of RAS <sup>G12D</sup> aspartic acid in tumors

Caroline E. Weller, G. Leslie Burnett, Lingyan Jiang et al. · Science · 2025 · 31 citations

Medicine, Oncology, Pharmacology +15

Abstract ND03: Discovery of RMC-9805, an oral, covalent tri-complex KRASG12D(ON) inhibitor

John E. Knox, G. Leslie Burnett, Caroline E. Weller et al. · Cancer Research · 2024 · 16 citations

Medicine, Oncology, Pharmacology +13

A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma

Caroline Broderick, Riccardo Mezzadra, Exequiel M. Sisso et al. · Cancer Discovery · 2025 · 15 citations · Full text

Medicine, Immunology, Oncology +17

1–4 of 4